| IVBXF Stock | | | USD 4.85 0.24 4.72% |
Insider
Min Liu is Chief Officer of Innovent Biologics
| Phone | 86 512 6956 6088 |
| Web | https://www.innoventbio.com |
Innovent Biologics Management Efficiency
The company has return on total asset
(ROA) of
(0.1372) % which means that it has lost $0.1372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.287) %, meaning that it generated substantial loss on money invested by shareholders. Innovent Biologics' management efficiency ratios could be used to measure how well Innovent Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
Innovent Biologics has accumulated 2.02
B in total debt with debt to equity ratio
(D/E) of 0.29, which may suggest the company is not taking enough advantage from borrowing. Innovent Biologics has a current ratio of 3.15, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Innovent Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, Innovent Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovent Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovent to invest in growth at high rates of return. When we think about Innovent Biologics' use of debt, we should always consider it together with cash and equity.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people. Innovent Biologics [IVBXF] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Innovent Biologics Leadership Team
Elected by the shareholders, the Innovent Biologics' board of directors comprises two types of representatives: Innovent Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovent. The board's role is to monitor Innovent Biologics' management team and ensure that shareholders' interests are well served. Innovent Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovent Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Min Liu, Chief Officer | |
| Blake Salisbury, Sr Devel | |
| Eduard MD, Pres USA | |
| Yong MD, President | |
| Vivian Zhang, Chief Officer | |
| Dongming Wang, VP Quality | |
| Changshou Gao, VP CTO | |
| Yanju Wang, Joint Sec | |
| Hao Ede, CFO Director | |
| DeChao Yu, Chairman CoFounder | |
Innovent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Innovent Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.